4-Hydroxytamoxifen,Afimoxifene

Catalog No.S7827 Synonyms: Afimoxifene

4-Hydroxytamoxifen,Afimoxifene Chemical Structure

Molecular Weight(MW): 387.51

4-Hydroxytamoxifen is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.

Size Price Stock Quantity  
USD 117 In stock
USD 497 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 5 Publications

1 Customer Review

  • CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments.

    Oncogene, 2016, 36(16):2255-2264. 4-Hydroxytamoxifen,Afimoxifene purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description 4-Hydroxytamoxifen is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.
In vitro

4-OHT is a potent activator of ER and has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. It has significant dose and time-dependent direct effects to alter the contractile function of isolated adult rat cardiac myocytes[1]. 4-HT activates on-target modification frequency for intein-Cas9 variants [3].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 cells MVvQdo9tcW[ncnH0bY9vKGG|c3H5 MVfJcohq[mm2aX;uJI9nKGW|dILv[4VvNXO2aX31cIF1\WRiTVPGMVch[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwQVAvPSCwTR?= MX:5OVQ5QDF5
MCF7 cells MYXGeY5kfGmxbjDhd5NigQ>? MWXJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCPQ1[tO{BjemWjc4SgeJVud3JiY3XscJMhfXOrbnegUWNHNTdiYYPzZZktKEmFNUC9PE42KG6P NELFdVIyOjh{NUmzOS=>
MCF7 cells NHvVWoJRem:uaX\ldoF1cW:wIHHzd4F6 NUXvTYxVPzJiaB?= M2rOPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[ZN1em:pZX6gdoVk\XC2b4Kg[IVx\W6mZX70JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkGwO{DPxE1? NVj1[lFqOTh6M{WxO|Y>
MCF7 cells NH\kN4dRem:uaX\ldoF1cW:wIHHzd4F6 NWKzVo57OjRiaB?= NHOxPXlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD16LkWgcm0> NX3lTo1IOTh{N{KyOVY>
T47D:C:4:2 cells MlflSpVv[3Srb36gZZN{[Xl? MUXFd5Rzd2enbnnjJIFkfGm4aYT5JIF1KHerbHSgeJlx\SCHUjDhcJBp[SCneIDy[ZN{\WRiaX6gWFQ4TDqFOkS6NkBk\WyuczDjc4V5eHKnc4Ppcoch\XO2cn;n[Y4hemW|cH;ud4Uh\WynbXXueEBjgSCmdXXsJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NEG4ZZYzODN|NEO2PC=>
MDA-MB-231 cells MXnGeY5kfGmxbjDhd5NigQ>? Mk\yN{Bl[Xm| M1LxemN6fG:|dHH0bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDNiZHH5d{BjgSCvaXPyc5RqfGW{IHHzd4F6 NEHCc2IzODV7OEW1OS=>
PC3 cells MnKwVJJwdGmoZYLheIlwdiCjc4PhfS=> M4ez[|Q5KGh? MkfaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDhcoRzd2enbjDy[YNmeHSxcj3k[YZq[2mnboSgbJVu[W5iUFOzJINmdGy|IHnuZ5Vj[XSnZDD3bZRpKDBwNjDuUUBw\iCnc4TyZYRqd2xiYX7kJFAvPyCwTTDv[kB1\XO2b4P0[ZJwdmViYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO|YYmsJGdKPTB;Nz61PFU4QCEQvF2= M16wSFIyPTF|Mke1
DU145 cells M360T3Bzd2yrZnXyZZRqd25iYYPzZZk> NHXEXI01QCCq MoPmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDhcoRzd2enbjDy[YNmeHSxcj3k[YZq[2mnboSgbJVu[W5iRGWxOFUh[2WubIOgbY5kfWKjdHXkJJdqfGhiMD62JI5OKG:oIHXzeJJi\GmxbDDhcoQhOC55IH7NJI9nKHSnc4Tvd5Rmem:wZTDh[pRmeiB2ODDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2xNE44OTV{IN88US=> NX\COmhxOjF3MUOyO|U>
LNCAP cells MnTRVJJwdGmoZYLheIlwdiCjc4PhfS=> M2L0TFQ5KGh? MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyQQ1HQJINmdGy|IHX4dJJme3OrbnegZY5lem:pZX6gdoVk\XC2b4KgbY5kfWKjdHXkJJdqfGhiMD62JI5OKG:oIHXzeJJi\GmxbDDhcoQhOC55IH7NJI9nKHSnc4Tvd5Rmem:wZTDh[pRmeiB2ODDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME24MlMyPzZ2IN88US=> MkfBNlE2OTN{N{W=
T47D cells MmjkR5l1d3SxeHnjbZR6KGG|c3H5 Mo\0OUBl[Xm| NFfGbllEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVPDeGIHPlcIx{KGGodHXyJFUh\GG7czygTWM2OD1yLkKxJO69VQ>? MmrXNlM5PjR7Mki=
MDA-MB-231 cells M4jUfHBzd2yrZnXyZZRqd25iYYPzZZk> NWW0VoZGOjRiaB?= NXnWSnJxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OTBwNDFOwG0> MknnNlQyQDlyNUW=
MCF7 cells NHjy[JhHfW6ldHnvckBie3OjeR?= NFPTdZcyOCEQvF2= MkTKOkBp NXzGOGN[XXC{ZXf1cIF1cW:wIH;mJGVT[WyyaHGgdJJwfGWrbjDs[ZZmdHNiaX6gbJVu[W5iTVPGO{Bk\WyuczDheEAyOCC3TTDh[pRmeiB4IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m NGr1[Y4zPDN|Mk[zNC=>
SKOV3 cells NXLSOmc4TnWwY4Tpc44h[XO|YYm= MlzKOFghcA>? MXfBcpRq[2GwY3XyJIFo[Wmwc4SgbJVu[W5iU1vPWlMh[2WubIOgc5ZmemW6cILld5NqdmdiUD3ndEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUeuOFYh|ryP NGfhVZkzPDl2NkG0OS=>
MDA-MB-231 cells MX3GeY5kfGmxbjDhd5NigQ>? MlTnOFghcA>? MXPBcpRq[2GwY3XyJIFo[Wmwc4SgbJVu[W5iRWKtdI9{cXSrdnWgUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTVwNDFOwG0> M3jnRlI1QTR4MUS1
MCF7 cells Ml\zSpVv[3Srb36gZZN{[Xl? NWrXfWw{PDhiaB?= NVv5NJJnSW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJGVTNXCxc3n0bZZmKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF06NjJizszN M324blI1QTR4MUS1
MDA-MB-231 cells NGrPeVhHfW6ldHnvckBie3OjeR?= NGK0UXA1QCCq M{H5TWFvfGmlYX7j[ZIh[WejaX7zeEBpfW2jbjDFVk1v\WejdHn2[UBOTEFvTVKtNlMyKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;Nj6yJO69VQ>? M3fnT|I1QTR4MUS1
MCF7 cells NF3qXWdHfW6ldHnvckBie3OjeR?= NXf3XVNxOjVyIITvJFUxOCCwTR?= MVO1JIRigXN? MYPBcpRq[2GwY3XyJIFo[Wmwc4SgbJVu[W5iRWKtdI9{cXSrdnWgUWNHPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIV{fHKjZHnvcE1qdmS3Y3XkJINmdGxicILvcIln\XKjdHnvckBifCB{NUCgeI8hPTByIH7NJIFnfGW{IEWg[IF6ew>? MV:yOFk1PjF2NR?=
MCF7 cells MYrDfZRwfG:6aXPpeJkh[XO|YYm= MVS0PEBp M1;0XGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xN{43KM7:TR?= NFjPcnMzPTZzOEW5OS=>
DU145 cells Mo\JVJJwdGmoZYLheIlwdiCjc4PhfS=> NEfERoQ4OiCq NILzUldCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yPS5|IN88US=> NV;MRZY4OjV7OUOyOlk>
african green monkey Vero cells NFv6RpZRem:uaX\ldoF1cW:wIHHzd4F6 NFHxZoE4OiCq NWHMdHh{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBi\nKrY3HuJIdz\WWwIH3vcotmgSCYZYLvJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xOU4yKM7:TR?= MUOyOVk6OzJ4OR?=
BT-20 cells MWrQdo9tcW[ncnH0bY9vKGG|c3H5 NV3yVppbUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KHC{b3zp[oVz[XSrb36gc4YhSlRvMkCgZ4VtdHNiaX6gdJJme2WwY3Wgc4YhXFCHIHH0JFEx\S13IF2gZ49v[2WwdILheIlwdg>? M2PWe|I4Pjl4OEG=
Ishikawa endometrial cells MmXLSpVv[3Srb36gZZN{[Xl? NEn5Z5lCdnSjZ3;ubZN1KGGldHn2bZR6KGG|IHnubIljcXSrb36gc4YhOSCwTTCxO{1j\XSjLXXzeJJi\GmxbDDzeIlufWyjdHXkJIFtc2GuaX7lJJBpd3OyaHH0ZZNmKGmwZIXjeIlwdiCrbjDJd4hqc2G5YTDlcoRwdWW2cnnhcEBk\WyuczygTWM2OD1yLkWxJO69VQ>? MnXmNVU{QDB{MEi=
MCF-7-2a cells MmLTSpVv[3Srb36gZZN{[Xl? M1vWUmlvcGmkaYTpc44hd2ZiZYP0doFlcW:uIHnu[JVk\WRiZYP0do9o\W5icnXj[ZB1d3JidILhcpNkemmydHnvcoFtKGGldHn2ZZRqd25iaX6gUWNHNTdvMnGgZ4VtdHNuIFnDOVA:OC5yMEeg{txO MlTNNVI3PzJ{NEm=
Calu-1 cells MWjGeY5kfGmxbjDhd5NigQ>? NYHuUJJtOzBibXnudy=> MVLJcohq[mm2aX;uJI9nKFCOREGgbY4hcHWvYX6gR4FtfS1zIHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJJBpd3OyaHH0bYR6dGK3dHHuc4wuY2R7XTDwdo9lfWO2aX;uJIFnfGW{IEOwJI1qdnNiYomgcYF{eyC|cHXjeJJwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUSuPEDPxE1? M{H4OVE6OTN4OUe1
MCF12A cells MXHQdo9tcW[ncnH0bY9vKGG|c3H5 MmCxOFghcA>? NYrEVWJWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUWNHOTKDIHPlcIx{KGmwY4XiZZRm\CC5aYToJFAvODB|IH7NJI9nKGW|dILh[IlwdCCjbnSgNE4xOSCwTTDv[kB1\XO2b4P0[ZJwdmViYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO|YYmgbY4heHKnc3XuZ4Uhd2ZiNTWg[oV1[WxiYn;2bY5mKHOncoXtMEBIUTVyPUOuN|EyOzFizszN MkXCNlE2OTN{N{W=
MCF7:WS8 cells Ml[0SpVv[3Srb36gZZN{[Xl? MV3BZ5RqfmG2aX;uJI9nKGi3bXHuJGVTKGmwIHj1cYFvKE2FRke6W3M5KGOnbHzzJIV5eHKnc4Ppcoch\XO2cn;n[Y4hemW|cH;ud4l3\SCnbHXt[Y51KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> MViyNFM{PDN4OB?=
HEK293 cell MXnGeY5kfGmxbjDhd5NigQ>? MY[zNEBucW6| NF76RnFKdmirYnn0bY9vKG:oIFfGVE11[WepZXSgbJVu[W5iUFzENkBmgHC{ZYPz[YQhcW5iaIXtZY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHCqb4PwbIF1cWS7bHL1eIFvd2xvW3S5YUBxem:mdXP0bY9vKGGodHXyJFMxKG2rboOgZpkhdWG|czDzdIVkfHKxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVAvODR2IN88US=> NHTPTHMyQTF|Nkm3OS=>
MCF12A cells MlT3VJJwdGmoZYLheIlwdiCjc4PhfS=> M2LrdFQ5KGh? MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHXzeJJw\2WwIILlZ4VxfG:{LXTl[olkcWWwdDDoeY1idiCPQ1[xNmEh[2WubIOgbY5kfWKjdHXkJJdqfGhiMD6wOkBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwMEegcm0hd2ZidHXzeI9{fGW{b37lJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJIZmfGGuIHLveolv\SC|ZYL1cUBidmRiToXT[ZJ2dSxiR1m1NF0{Njh7MES1JO69VQ>? Mn\HNlE2OTN{N{W=
HEK293 cells M3;5XmZ2dmO2aX;uJIF{e2G7 NY\GVHRxSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBme3S{b3flckBz\WyjdHXkJJJm[2WydH;yJIdidW2jIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCJSUWwQVEvOzVizszN NVXi[lBNOjV|MEW2PFg>
rat GH3 cells NFi5THJHfW6ldHnvckBie3OjeR?= MW[0PEBp NFz4TXNCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSJIlvKHKjdDDHTFMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDld5Rz[WSrb3ytbY5lfWOnZDDwdo9t[WO2aX6g[4Vv\SCneIDy[ZN{cW:wIHH0JFExLy14IF2gZYZ1\XJiNEigbJJ{KGK7IGLUMXBEWiCjbnHsfZNqew>? M33mPVI1QDB3MUm5
MCF7:WS8 cells MoPWSpVv[3Srb36gZZN{[Xl? Mm\zOFghcA>? Mkn0RYdwdmm|dDDhZ5Rqfmm2eTDheEBGWiCrbjDoeY1idiCPQ1[3PndUQCClZXzsd{Bie3Onc4Pl[EBieyCJUlXCNUBo\W6nIHX4dJJme3Orb36gZZQhOTBpLU[gUUBi\nSncjC0PEBpenNiYomgVnQuWEOUIHHuZYx6e2m| NFu5bVUzPDhyNUG5PS=>
rat GH3 cells NX\JT3hOTnWwY4Tpc44h[XO|YYm= MojVOFghcA>? MmXjRY51[WexbnnzeEBi[3Srdnn0fUBifCCHUjDpckBz[XRiR1izJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiZYP0doFlcW:uLXnu[JVk\WRicILvcIFkfGmwIHflcoUh\XiycnXzd4lwdiCjdDCxNEcuOTBidH:gNVAoNTZiTTDh[pRmeiB2ODDodpMh[nliUmStVGNTKGGwYXz5d4l{ NGLq[pUzPDhyNUG5PS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK / p-MEK / MEK1 / MEK2 / p21 / Cyclin D1 ; 

PubMed: 26163823     


LNCaP-Raf:ER cells were treated with increasing doses of 4-hydroxytamoxifen for 2 days. The bottom panel indicates densitometry of MEK1 and MEK2 signals. Data (mean ± standard error) are from two independent experiments. Pearson’s r = 0.823 for MEK1 and −0.673 for MEK2. 

26163823
Growth inhibition assay
Cell viability; 

PubMed: 26014809     


Dose-dependent effect of 4-hydroxytamoxifen on survival of T47D, MCF-7 and BT-474 cell lines after 96 h of treatment. Control samples were treated with appropriate concentrations of DMSO. Viability was assayed by MTT method.

26014809

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Adult Rat and Mouse Cardiac Myocytes
  • Concentrations: 0, 0.5, 1, 3, 5, and 10 µM
  • Incubation Time: 15-45 min
  • Method:

    For sarcomere length measurements, cells are covered in Tyrode’s containing 4OHT, allowed to reach 36 ± 1°C, and then stimulated at 0.2 Hz.


    (Only for Reference)
Animal Research:

[2]

- Collapse
  • Animal Models: Sprague-Dawley rats
  • Formulation: dissolved in 200 μl tricaprylin
  • Dosages: 21 mg/kg, 54 μmol/kg
  • Administration: oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 77 mg/mL (198.7 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 387.51
Formula

C26H29NO2

CAS No. 68392-35-8
Storage powder
in solvent
Synonyms Afimoxifene

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03199963 Terminated Drug: 4-OH tamoxifen|Drug: Placebo Mammographic Breast Density BHR Pharma LLC August 21 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Estrogen/progestogen Receptor Signaling Pathway Map

Related Estrogen/progestogen Receptor Products

Tags: buy 4-Hydroxytamoxifen,Afimoxifene | 4-Hydroxytamoxifen,Afimoxifene supplier | purchase 4-Hydroxytamoxifen,Afimoxifene | 4-Hydroxytamoxifen,Afimoxifene cost | 4-Hydroxytamoxifen,Afimoxifene manufacturer | order 4-Hydroxytamoxifen,Afimoxifene | 4-Hydroxytamoxifen,Afimoxifene distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID